iShares MSCI印度ETF INDA 深 沪
交易中 10-06 10:26:15 美东时间
46.745
+0.195
+0.42%
华盛通- 最 高50.28
- 今 开46.89
- 成交量 124.29万股
- 最 低 46.19
- 昨 收 46.55
- 总市值 486.15万
- 52周最高 55.495
- 市盈率 静 --
- 换手率 1195.08%
- 52周最低 45.2118
- 委 比 -45.67%
- 总股本 0.00亿
- 历史最高 59.0906
- 量 比 2.85
- 振 幅 8.79%
- 历史最低 17.0215
- 每 手 1
- 风险率 2.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. announced the sale of approximately $2.3 million in convertible promissory notes and warrants, as part of a $5 million offering. The notes mature in July 2026, bear 6% interest, and convert into common stock at 80% of the average closing price up to $0.40. Warrants for 200% of conversion shares will follow. Proceeds will fund research, including a Phase 1b/2 trial, and general corporate use.
2025-06-13 12:00
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Indaptus Therapeutics begins a new trial arm to study the safety, dosing, and anti-tumor activity of combining Decoy20 with Beigene's PD-1 inhibitor tislelizumab in patients with advanced solid tumors that have not responded to prior checkpoint inhibitors or are typically unresponsive.
2025-06-02 12:00
Reported Earlier, CAE Secures U.S. Navy Foreign Military Sales Contract To Support MH-60R Pilot And Mission Crew Training For India; Foreign Military Sales Contract Valued At $57M
https://verticalmag.com/press-releases/cae-secures-u-s-navy-foreign-military-sales-contract-to-support-mh-60r-training-for-india/ CAE announced that CAE Defense & Security USA has been awarded a contract by the United States Navy under a U.S. Foreign Military Sales (FMS) program to provide two train...
2024-09-04 21:59
